来源：智通财经网 轻松健康(02661)涨超9%，高见74.8港元，较招股价22.68港元已涨近230%。截至发稿，涨8.83%，报 74.6港元，成交额2598.09万港元。 国投证券国际发布研报称，轻松健康主要业务为健康相关及保险相关解决方案，公司于2016年开始布局 保险相关服务，截至2025年6月30日，保险相关服务覆盖58家保险公司合作伙伴，覆盖2620万投保人， 累计保费收入54亿元。公司2023年推出数字营销（科普服务），客户主要为医药公司，帮助其连接目标 用户群体，业务逐步转型，持续丰富数字医学研究辅助服务、综合健康服务套餐等业务。 该行指出，公司具备一定的生态效应，2024年约30%的保单持有人在购买保险钱已经为健康相关服务的 客户，健康服务和保险服务协同已有验证；保险服务相关业务的客户留存率较高，1H25为53%；健康 服务收入呈高增速。 ...

国投证券国际发布研报称，轻松健康主要业务为健康相关及保险相关解决方案，公司于2016年开始布局 保险相关服务，截至2025年6月30日，保险相关服务覆盖58家保险公司合作伙伴，覆盖2620万投保人， 累计保费收入54亿元。公司2023年推出数字营销（科普服务），客户主要为医药公司，帮助其连接目标 用户群体，业务逐步转型，持续丰富数字医学研究辅助服务、综合健康服务套餐等业务。 该行指出，公司具备一定的生态效应，2024年约30%的保单持有人在购买保险钱已经为健康相关服务的 客户，健康服务和保险服务协同已有验证；保险服务相关业务的客户留存率较高，1H25为53%；健康 服务收入呈高增速。 智通财经APP获悉，轻松健康(02661)涨超9%，高见74.8港元，较招股价22.68港元已涨近230%。截至发 稿，涨8.83%，报74.6港元，成交额2598.09万港元。 ...

Core Viewpoint - The company, Easy Health Group, is updating its prospectus for an IPO on the Hong Kong Stock Exchange, with CICC and China Merchants Securities International as joint sponsors [1]. Company Overview - Easy Health Group is a one-stop platform in China focusing on providing digital integrated health services and health insurance solutions. It ranks 10th in the digital integrated health services and health insurance market in China based on projected 2024 revenue [4]. - The company aims to offer accessible, precise, and affordable health solutions to individuals in need, including screening promotion, health checks, medical appointment services, and health product sales [4]. Service Offerings - The company provides a variety of personalized health services targeting users seeking comprehensive health solutions, including screening promotion and consultation services, integrated health service packages, digital marketing (health education), and digital medical research support [4][5][6][7][8]. - Digital marketing services were launched in 2023, offering tailored digital marketing solutions to pharmaceutical companies and charitable foundations, with a significant increase in the number of clients and health education content produced over the years [5]. - The company supports the pharmaceutical industry by providing comprehensive solutions for medical research, including real-world study design and clinical trial data analysis, with a growing number of clients [6]. Financial Performance - The company reported revenues of approximately RMB 490 million in 2023, RMB 945 million in 2024, and projected RMB 656 million for the first half of 2025. The profits for the same periods were RMB 73.62 million, RMB 10.39 million, and RMB 86.05 million respectively [9][10]. - The revenue cost and gross profit margins have shown fluctuations, with gross profit margins of 82.6% in 2022, decreasing to 32.5% by 2025 [10].